All Stories

  1. A Genome-Wide Association Study of Oxypurinol Concentrations in Patients Treated with Allopurinol
  2. Data from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  3. Data from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  4. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  5. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  6. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  7. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  8. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  9. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  10. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  11. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  12. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  13. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  14. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  15. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  16. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  17. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  18. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  19. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  20. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  21. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  22. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  23. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  24. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  25. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  26. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  27. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  28. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  29. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  30. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  31. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  32. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  33. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  34. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  35. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  36. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  37. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  38. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  39. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  40. Data from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  41. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  42. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  43. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  44. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  45. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  46. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  47. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  48. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  49. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  50. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  51. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  52. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  53. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  54. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  55. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  56. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  57. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  58. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  59. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  60. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  61. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  62. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  63. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  64. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  65. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  66. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  67. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  68. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  69. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  70. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  71. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  72. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  73. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  74. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  75. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  76. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  77. Assessing the role of rare pathogenic variants in heart failure progression by exome sequencing in 8,089 patients
  78. Interplay between hereditary and acquired factors determines the neutrophil counts in older individuals
  79. Data from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  80. Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  81. Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  82. Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  83. Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  84. Figure 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  85. Figure 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  86. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  87. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  88. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  89. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  90. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  91. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  92. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  93. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  94. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  95. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  96. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  97. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  98. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  99. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  100. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  101. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  102. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  103. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  104. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  105. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  106. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  107. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  108. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  109. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  110. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  111. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  112. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  113. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  114. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  115. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  116. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  117. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  118. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  119. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  120. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  121. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  122. Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  123. Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  124. Data from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  125. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  126. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  127. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  128. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  129. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  130. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  131. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  132. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  133. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  134. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  135. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  136. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  137. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  138. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  139. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  140. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  141. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  142. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  143. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  144. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  145. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  146. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  147. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  148. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  149. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  150. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  151. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  152. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  153. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  154. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  155. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  156. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  157. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  158. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  159. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  160. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  161. Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  162. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome
  163. Abstract 10075: Hematopoietic Mosaic Chromosomal Alterations and Cardiovascular Disease-Related Deaths Among Cancer Survivors: An Analysis of the UK Biobank
  164. Including diverse and admixed populations in genetic epidemiology research
  165. An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites
  166. Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19
  167. Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof‐of‐concept study
  168. Gender matters in heart attack prevention: higher femininity linked to angina diagnosis in men
  169. Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation
  170. A sex-specific evolutionary interaction between ADCY9 and CETP
  171. Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
  172. The genomics of heart failure: design and rationale of the HERMES consortium
  173. Multitrait GWAS to connect disease variants and biological mechanisms
  174. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
  175. Genetics of symptom remission in outpatients with COVID-19
  176. A sex-specific evolutionary interaction betweenADCY9andCETP
  177. Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials
  178. Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT
  179. Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib
  180. Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality
  181. ExPheWas: a browser for gene-based pheWAS associations
  182. Genetics of symptom remission in outpatients with COVID-19
  183. Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women
  184. Comparative effectiveness and safety of high‐dose rivaroxaban and apixaban for atrial fibrillation: A propensity score‐matched cohort study
  185. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect
  186. The associations of hostility and defensiveness with telomere length are influenced by sex and health status
  187. A genetic association study of heart failure: more evidence for the role of BAG3 in idiopathic dilated cardiomyopathy
  188. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
  189. Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure
  190. Statin Initiation: Guideline Concordance and Characteristics of New Users in Quebec, Canada
  191. A genetic model of ivabradine recapitulates results from randomized clinical trials
  192. Multitrait genetic-phenotype associations to connect disease variants and biological mechanisms
  193. High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential
  194. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
  195. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta‐analysis
  196. Heritability of 596 lipid species and genetic correlation with cardiovascular traits in the Busselton Family Heart Study
  197. Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA‐HF trial
  198. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib
  199. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
  200. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation
  201. Inherited Chromosomally Integrated Human Herpesvirus 6 Demonstrates Tissue-Specific RNA Expression In Vivo That Correlates with an Increased Antibody Immune Response
  202. Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes
  203. rs73185306 C/T Is Not a Predisposing Risk Factor for Inherited Chromosomally Integrated Human Herpesvirus 6A/B
  204. Inherited chromosomally integrated HHV-6 demonstrates tissue-specific RNA expressionin vivothat correlates with increased antibody immune response
  205. Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity
  206. Validation of Genome-Wide Polygenic Risk Scores for Coronary Artery Disease in French Canadians
  207. Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events
  208. Subsequent Event Risk in Individuals With Established Coronary Heart Disease
  209. Lipoprotein (a), arterial inflammation, and PCSK9 inhibition
  210. Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution
  211. Validation of genome-wide polygenic risk scores for coronary artery disease in French Canadians
  212. Biomarkers of dementia in obstructive sleep apnea
  213. Pharmacogenetic content of commercial genome-wide genotyping arrays
  214. Randomized Clinical Trial Needed to Confirm Whether Dalcetrapib Improves Outcomes for Specific ADCY9 Genotype
  215. Variants at the APOE/C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of High‐Density Lipoprotein Cholesterol
  216. Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A
  217. Protein-Coding Variants Implicate Novel Genes Related to Lipid Homeostasis Contributing to Body Fat Distribution
  218. Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines
  219. Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study
  220. Pharmacogenomics of blood lipid regulation
  221. A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure
  222. A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention
  223. Nuclear receptor gene polymorphisms and warfarin dose requirements in the Quebec Warfarin Cohort
  224. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity
  225. Polygenic determinants in extremes of high-density lipoprotein cholesterol
  226. Exome-wide association study of plasma lipids in >300,000 individuals
  227. Precision medicine to change the landscape of cardiovascular drug development
  228. Impact of Selection Bias on Estimation of Subsequent Event Risk
  229. Identification of the genetic determinants responsible for retinal degeneration in families of Mexican descent
  230. Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies
  231. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions
  232. CKing Precision in the Interpretation of Diagnostic Biomarkers
  233. Diagnosis, Prevalence, Awareness, Treatment, Prevention, and Control of Hypertension in Cameroon: Protocol for a Systematic Review and Meta-Analysis of Clinic-Based and Community-Based Studies
  234. Protein-altering and regulatory genetic variants near GATA4 implicated in bicuspid aortic valve
  235. CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction
  236. Methylomic changes in individuals with psychosis, prenatally exposed to endocrine disrupting compounds: Lessons from diethylstilbestrol
  237. CETP
  238. Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease
  239. Pharmacogenomic approaches to lipid-regulating trials
  240. Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically
  241. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality
  242. Paternal Age Explains a Major Portion of De Novo Germline Mutation Rate Variability in Healthy Individuals
  243. A model to assess the cost–effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine
  244. Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk population
  245. Meta-analysis of genome-wide association studies of HDL cholesterol response to statins
  246. genipe: an automated genome-wide imputation pipeline with automatic reporting and statistical tools
  247. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation
  248. Whole-genome sequencing in French Canadians from Quebec
  249. Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits
  250. Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals
  251. DNA methylation signature of human fetal alcohol spectrum disorder
  252. Avoidance of Vitamin K−Rich Foods Is Common among Warfarin Users and Translates into Lower Usual Vitamin K Intakes
  253. Pillbox Use and INR Stability in a Prospective Cohort of New Warfarin Users
  254. Methylomic changes during conversion to psychosis
  255. Coding Variation inANGPTL4,LPL,andSVEP1and the Risk of Coronary Disease
  256. A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials
  257. An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance
  258. Testing the role of predicted gene knockouts in human anthropometric trait variation
  259. Resting heart rate as a predictor of aortic valve stenosis progression
  260. Pharmacogenomics to Revive Drug Development in Cardiovascular Disease
  261. Calcium Signaling Pathway GenesRUNX2andCACNA1CAre Associated With Calcific Aortic Valve DiseaseCLINICAL PERSPECTIVE
  262. Will personalized drugs for cardiovascular disease become an option? – Defining ‘Evidence-based personalized medicine’ for its implementation and future use
  263. Impact of regular physical activity on weekly warfarin dose requirement
  264. Mutation Burden of Rare Variants in Schizophrenia Candidate Genes
  265. Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review
  266. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice
  267. Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib
  268. Comparison of Sequencing Based CNV Discovery Methods Using Monozygotic Twin Quartets
  269. CKM and LILRB5 Are Associated With Serum Levels of Creatine Kinase
  270. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins
  271. Genetic Markers of Cisplatin-Induced Hearing Loss in Children
  272. Modifiers of (CAG)n instability in Machado–Joseph disease (MJD/SCA3) transmissions: an association study with DNA replication, repair and recombination genes
  273. Development of a broad-based ADME panel for use in pharmacogenomic studies
  274. Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis
  275. Novel presenilin mutations within Moroccan patients with Early-Onset Alzheimer’s Disease
  276. Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits
  277. Novel Mutations in the Amyloid Precursor Protein Gene within Moroccan Patients with Alzheimer's Disease
  278. Comparison of genotype clustering tools with rare variants
  279. Cuckoo search epistasis: a new method for exploring significant genetic interactions
  280. Validation of patient-reported warfarin dose in a prospective incident cohort study
  281. Evaluation of Links Between High-Density Lipoprotein Genetics, Functionality, and Aortic Valve Stenosis Risk in Humans
  282. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity
  283. pyGenClean: efficient tool for genetic data clean up before association testing
  284. Erratum: Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
  285. Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent
  286. Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children
  287. The Impact of Partial and Complete Loss-of-Function Mutations in Endothelial Lipase on High-Density Lipoprotein Levels and Functionality in Humans
  288. Institutional Profile: The Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre at the Montreal Heart Institute
  289. SRAP Polymorphisms Associated to Cell Wall Degradability in Lignified Stems of Alfalfa
  290. Pooled DNA Resequencing of 68 Myocardial Infarction Candidate Genes in French Canadians
  291. Rare Copy Number Variants Contribute to Congenital Left-Sided Heart Disease
  292. Genetic control of high density lipoprotein-cholesterol in AcB/BcA recombinant congenic strains of mice
  293. Segregation of LIPG, CETP, and GALNT2 Mutations in Caucasian Families with Extremely High HDL Cholesterol
  294. Assessment of Genetic Variability of Cell Wall Degradability for the Selection of Alfalfa with Improved Saccharification Efficiency
  295. PRKCB is associated with calcineurin inhibitor-induced renal dysfunction in heart transplant recipients
  296. Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children
  297. Molecular physiology and breeding at the crossroads of cold hardiness improvement
  298. Risk of congenital heart defects is influenced by genetic variation in folate metabolism
  299. Erratum to: Intron-length polymorphism identifies a Y2K4 dehydrin variant linked to superior freezing tolerance in alfalfa
  300. Validation of warfarin pharmacogenetic algorithms in clinical practice
  301. Intron-length polymorphism identifies a Y2K4 dehydrin variant linked to superior freezing tolerance in alfalfa
  302. Design and rationale of a genetic cohort study on congenital cardiac disease: experiences from a multi-institutional platform in Quebec
  303. Predicting Statin Induced Muscle Toxicity
  304. Fetal Alcohol Spectrum Disorders: Gene-Environment Interactions, Predictive Biomarkers, and the Relationship Between Structural Alterations in the Brain and Functional Outcomes
  305. Familial ventricular aneurysms and septal defects map to chromosome 10p15
  306. Positional cloning of a quantitative trait locus contributing to pain sensitivity: possible mediation by Tyrp1
  307. A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura
  308. Direct Measure of the De Novo Mutation Rate in Autism and Schizophrenia Cohorts
  309. Partitioning of copy-number genotypes in pedigrees
  310. Family Study of Restless Legs Syndrome in Quebec, Canada
  311. Mutations in DCC Cause Congenital Mirror Movements
  312. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia
  313. Genetic determinants of blood pressure reduction following potassium supplementation: and the candidates are…
  314. Genetics of bronchopulmonary dysplasia in the age of genomics
  315. Testing for Gene-Gene Interaction with AMMI Models
  316. Novel mutations in the sacsin gene in ataxia patients from Maritime Canada
  317. Genetic Studies
  318. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
  319. Genetic Modulation of Brugada Syndrome by a Common Polymorphism
  320. Application of principal component analysis to pharmacogenomic studies in Canada
  321. Association between cervical and intracranial dimensions and syringomyelia in the cavalier King Charles spaniel
  322. Mutation in Pyrroline-5-Carboxylate Reductase 1 Gene in Families with Cutis Laxa Type 2
  323. Application of Homozygosity Haplotype Analysis to Genetic Mapping with High-Density SNP Genotype Data
  324. Genetic predictors of depressive symptoms in cardiac patients
  325. The challenge of detecting epistasis (G×G Interactions): Genetic Analysis Workshop 16
  326. Autosomal-dominant locus for restless legs syndrome in French-Canadians on chromosome 16p12.1
  327. Génome Québec & Montreal Heart Institute Pharmacogenomics Centre: a translational pharmacogenomics platform – from R&D to the clinic
  328. Mutations in the calcium-related gene IL1RAPL1 are associated with autism
  329. A survey of the personalized medicine landscape
  330. Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan
  331. Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure
  332. A novel locus for idiopathic generalized epilepsy in French-Canadian families maps to 10p11
  333. No evidence that skewing of X chromosome inactivation patterns is transmitted to offspring in humans
  334. The Genetics of Congenital Amusia (Tone Deafness): A Family-Aggregation Study
  335. Mutations in the UBIAD1 Gene, Encoding a Potential Prenyltransferase, Are Causal for Schnyder Crystalline Corneal Dystrophy
  336. Syringomyelia in cavalier King Charles spaniels: the relationship between syrinx dimensions and pain
  337. Obesity and TCF7L2 variants' additive effect on type 2 diabetes risk in cardiac patients
  338. Molecular genetic studies of DMT1 on 12q in French‐Canadian restless legs syndrome patients and families
  339. Loss-of-function genetic diseases and the concept of pharmaceutical targets
  340. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations
  341. Lamin A/C mutations associated with familial and sporadic cases of dilated cardiomyopathy in Koreans
  342. Multistage designs in the genomic era: Providing balance in complex disease studies
  343. A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13
  344. Bootstrap Inference with Neural-Network Modeling for Gene-Disease Association Testing
  345. A new locus for autosomal dominant intracranial aneurysm, ANIB4, maps to chromosome 5p15.2-14.3
  346. Human monogenic disorders — a source of novel drug targets
  347. Common Genetic Vulnerability to Depressive Symptoms and Coronary Artery Disease: A Review and Development of Candidate Genes Related to Inflammation and Serotonin
  348. Autism spectrum disorders associated with X chromosome markers in French-Canadian males
  349. A Variant in XPNPEP2 Is Associated with Angioedema Induced by Angiotensin I–Converting Enzyme Inhibitors
  350. Analysis of microsatellite markers and single nucleotide polymorphisms in candidate genes for susceptibility to bipolar affective disorder in the chromosome 12Q24.31 region
  351. Chromosome 11-q24 region in Tourette syndrome: Association and linkage disequilibrium study in the French Canadian population
  352. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease
  353. The 14q restless legs syndrome locus in the French Canadian population
  354. Identification of a Novel Gene (HSN2) Causing Hereditary Sensory and Autonomic Neuropathy Type II through the Study of Canadian Genetic Isolates
  355. Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
  356. AnALS2gene mutation causes hereditary spastic paraplegia in a Pakistani kindred
  357. Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy
  358. Fine mapping the candidate region for peripheral neuropathy with or without agenesis of the corpus callosum in the French Canadian population
  359. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives
  360. Clouston hidrotic ectodermal dysplasia (HED): genetic homogeneity, presence of a founder effect in the French Canadian population and fine genetic mapping
  361. Genomic structure of the human GT334 (EHOC-1) gene mapping to 21q22.3